Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandra Ivars Rubio

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Oncologist|April 28, 2026
Effect of Patient Factors and Quality of Life on ECOG Assignment and Inter-Rater Agreement in Hospitalized Cancer PatientsNoel Blaya Boluda, Esmeralda García-Torralba, Alberto García-Romero, et al.
Scientific Reports|November 20, 2019
Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variablesAlejandra Ivars Rubio, Juan Carlos Yufera, Pilar de la Morena, et al.
Breast Cancer Research and Treatment|January 18, 2018
Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysisElisa García Garre, Ginés Luengo Gil, Silvia Montoro García, et al.
Cancers|June 22, 2023
Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast CancerEsmeralda García-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, et al.
Frontiers in Oncology|June 14, 2023
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (<i>AURKA</i> and <i>MYBL2</i>) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patientsEsmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, et al.
Breast Cancer Research and Treatment|March 7, 2024
Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypesEsmeralda Garcia-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Oncologist|April 28, 2026
Effect of Patient Factors and Quality of Life on ECOG Assignment and Inter-Rater Agreement in Hospitalized Cancer PatientsNoel Blaya Boluda, Esmeralda García-Torralba, Alberto García-Romero, et al.
Scientific Reports|November 20, 2019
Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variablesAlejandra Ivars Rubio, Juan Carlos Yufera, Pilar de la Morena, et al.
Breast Cancer Research and Treatment|January 18, 2018
Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysisElisa García Garre, Ginés Luengo Gil, Silvia Montoro García, et al.
Cancers|June 22, 2023
Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast CancerEsmeralda García-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, et al.
Frontiers in Oncology|June 14, 2023
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (<i>AURKA</i> and <i>MYBL2</i>) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patientsEsmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, et al.
Breast Cancer Research and Treatment|March 7, 2024
Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypesEsmeralda Garcia-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, et al.
Pageof 1